Author: Editor

Oliver Peacock, MD The University of Texas MD Anderson Cancer Center discusses his ASCO 2020 Abstract on Improving the AJCC/TNM staging classification for colorectal cancer: The prognostic impact of tumor deposits.Background:Tumor deposit (TD) detection currently plays a limited role in colorectal cancer ( CRC) staging other than for N1c classification. The purpose of this research was to evaluate the prognostic effect of TD among primary CRC patients, beyond the AJCC N1c classification. Methodology:Patients with stage 1 to 3 primary CRC diagnosed between 2010 and 2015 were reported from the Monitoring, Epidemiology and End Results (SEER) database. TD stratified cancer specific survival…

Philip Mack, Ph.D. of Mount Sinai answers the common questions he has received for his ASCO 2020 abstract on Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. Background : Longitudinal improvements in the occurrence of mutant alleles (MAF) have high potential to refine clinical management of targeted therapies. Methodology: S1403 was a first-line phase II analysis of afatinib w or w/o cetuximab in pts with EGFR-mutant NSCLC. 174 pts were randomized with 168 confirmed to be qualified between March 2015 and April 2018.…

Philip Mack, Ph.D. of Mount Sinai discusses his ASCO 2020 abstract on Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. Background : Longitudinal improvements in the occurrence of mutant alleles (MAF) have high potential to refine clinical management of targeted therapies. Methodology: S1403 was a first-line phase II analysis of afatinib w or w/o cetuximab in pts with EGFR-mutant NSCLC. 174 pts were randomized with 168 confirmed to be qualified between March 2015 and April 2018. Owing to futility, the study closed early.…

Senthil Damodaran, MD of MD Anderson shares his final thoughts on the Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F. Bottom line: NCI-MATCH (EAY131) is a platform study in which patients (pts) with solid tumors, lymphomas, or multiple myeloma are enrolled in targeted therapies based on subsequent genomic interest shifts (NCT02465060). In pts with PIK3CA mutations, Arm Z1F evaluated copanlisib, a highly selective, pan-Class 1 PI3 K inhibitor with predominant activity against both the δ and alpha isoforms. Methodology: Copanlisib (60 mg IV) was administered to Pts in 28-day cycles…

Senthil Damodaran, MD of MD Anderson talks about the common questions he receives about the Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F. Bottom line: NCI-MATCH (EAY131) is a platform study in which patients (pts) with solid tumors, lymphomas, or multiple myeloma are enrolled in targeted therapies based on subsequent genomic interest shifts (NCT02465060). In pts with PIK3CA mutations, Arm Z1F evaluated copanlisib, a highly selective, pan-Class 1 PI3 K inhibitor with predominant activity against both the δ and alpha isoforms. Methodology: Copanlisib (60 mg IV) was administered to Pts…

Wilson H. Miller, MD Jewish General Hospital discusses an ASCO 2020 abstract entitled A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer. Context: LY2880070 (LY) is an orally administered, selective control-point kinase 1 (Chk1) adenosine triphosphate competitive inhibitor. LY blocks the response of the checkpoint, and inhibition of Chk1 results in apoptosis induced by mitotic catastrophe. Approaches: This two-part, open-label multicenter research investigates LY ‘s protection, pharmacokinetics (PK) and anti-tumor activity in patients with advanced or metastatic cancers. The main purpose of this research was to determine the maximum tolerated dose…

Senthil Damodaran, MD of MD Anderson explains the Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F Bottom line: NCI-MATCH (EAY131) is a platform study in which patients (pts) with solid tumors, lymphomas, or multiple myeloma are enrolled in targeted therapies based on subsequent genomic interest shifts (NCT02465060). In pts with PIK3CA mutations, Arm Z1F evaluated copanlisib, a highly selective, pan-Class 1 PI3 K inhibitor with predominant activity against both the δ and alpha isoforms. Methodology: Copanlisib (60 mg IV) was administered to Pts in 28-day cycles on days 1, 8,…

Jason P Sheehan, MD of the University of Virginia speaks about his final thoughts on the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor study. The University of Virginia School of Medicine’s revolutionary use of centered ultrasound is showing promise against glioblastoma, the deadliest brain tumor, and may prove useful against other cancers that are difficult to treat. With a drug that sensitizes them to sound waves, the procedure strikes cancer cells, then blasts them with concentrated ultrasound. The sound waves produce tiny bubbles within the cancer cells which cause them to die. The work is early, with researchers testing…

Lindsey Rolfe at Clovis Oncology outlines a New Preclinical Data on ALKS 4230 in Combination With Lucitanib The research assessed the antitumor efficacy and mechanism of action of mALKS 4230, ALKS 4230 mouse ortholog, and lucitanib as monotherapy in conjunction with a preclinical syngeneic colon cancer mouse model. The combination of mALKS 4230 and lucitanib resulted in a dose-dependent, long-lasting complete response (absence of any detectable tumor) and improved survival compared to treatment with mALKS 4230 and lucitanib monotherapy. The main findings set out in the poster include: In the group that received the higher dose of mALKS 4230 (out…

Jason P Sheehan, MD of the University of Virginia explains how this will affect clinicians today, the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor study. The University of Virginia School of Medicine’s revolutionary use of centered ultrasound is showing promise against glioblastoma, the deadliest brain tumor, and may prove useful against other cancers that are difficult to treat. With a drug that sensitizes them to sound waves, the procedure strikes cancer cells, then blasts them with concentrated ultrasound. The sound waves produce tiny bubbles within the cancer cells which cause them to die. The work is early, with researchers…

Jason P Sheehan, MD of the University of Virginia discusses the common questions he receives about the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor study. The University of Virginia School of Medicine’s revolutionary use of centered ultrasound is showing promise against glioblastoma, the deadliest brain tumor, and may prove useful against other cancers that are difficult to treat. With a drug that sensitizes them to sound waves, the procedure strikes cancer cells, then blasts them with concentrated ultrasound. The sound waves produce tiny bubbles within the cancer cells which cause them to die. The work is early, with researchers…

Daniel Becker MD at NYU Langone discusses an ASCO 2020 abstract entitled Exploring the Cancer Genome Atlas (TCGA) for the molecular profile of young onset colorectal cancers. Background: The incidence and mortality of colorectal cancer ( CRC) has been decreasing, partially due to increased screening implementation, but the incidence among patients under 50 (young onset, YO) is increasing at a rate of 2 percent per year. The cause of this growing occurrence is still poorly understood, but variations in mutation profiles may help to explain pathogenesis, prognosis and identify therapy targets. Approaches: For 488 TCGA CRC patients, genomic and clinical…

Jason P Sheehan, MD of the University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor. The University of Virginia School of Medicine’s revolutionary use of centered ultrasound is showing promise against glioblastoma, the deadliest brain tumor, and may prove useful against other cancers that are difficult to treat. With a drug that sensitizes them to sound waves, the procedure strikes cancer cells, then blasts them with concentrated ultrasound. The sound waves produce tiny bubbles within the cancer cells which cause them to die. The work is early, with researchers testing the idea in lab dishes on…

Kristen Hege, MD – Bristol Myers Squibb discusses Phase 1 proof-of-concept data (via an oral presentation) on novel CELMoD CC-92480 from ASCO 2020. Background: CC-92480 is a novel cereblon E3 ligase modulator (CELMoD) agent designed to allow Ikaros and Aiolos to degrade quickly and maximally. In vitro, it has increased antiproliferative and tumoricidal activity with high immune stimulating activity in MM cell lines, including those resistant to lenalidomide (LEN) and pomalidomide (POM). Methods: Phase 1, multicenter, maximum tolerated dose (MTD) dose escalation analysis, suggested phase 2 dose, protection, tolerability, and pharmacokinetics of CC-92480 + DEX in highly pretreated RRMM pts.…

Filip Janku, MD at MD Anderson discusses an ASCO 2020 abstract entitled Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Bottom line: IM156, a novel oral potent biguanide OXPHOS inhibitor of the mitochondrial electron transport chain’s Protein Complex 1 (PC1), induces phosphorylation of AMPK, the downstream effects of which are harmful to energy stress-prone OXPHOS-dependent cancer cells. In solid tumor and hematologic malignancy models, preclinical studies with IM156 showed activity as a single agent and in combinations. Approaches: This was an open label, first-in-human, multi-center, dose-escalation study using a…

Kristen Hege, MD – Bristol Myers Squibb discusses Phase 1 proof-of-concept data (via an oral presentation) on novel CELMoD CC-92480 from ASCO 2020.Background: CC-92480 is a novel cereblon E3 ligase modulator (CELMoD) agent designed to allow Ikaros and Aiolos to degrade quickly and maximally. In vitro, it has increased antiproliferative and tumoricidal activity with high immune stimulating activity in MM cell lines, including those resistant to lenalidomide (LEN) and pomalidomide (POM).Methods: Phase 1, multicenter, maximum tolerated dose (MTD) dose escalation analysis, suggested phase 2 dose, protection, tolerability, and pharmacokinetics of CC-92480 + DEX in highly pretreated RRMM pts. On or…

Haiying Cheng, MD at Albert Einstein Cancer Center discusses an ASCO 2020 abstract entitled RICTOR amplification as a novel therapeutic target for lung cancer brain metastases Around 20% to 50% of advanced lung cancer patients experience brain metastases correlated with debilitating cognitive dysfunction and a dismal prognosis. Very few studies investigating the genomics of brain metastases in lung cancer have been performed. Approaches: We studied extensively the occurrence of PI3K / AKT / RICTOR / mTOR pathway aberrations at primary and metastatic sites using an comprehensive database of NGS (FoundationOne) 11845 cases of lung adenocarcinoma. In orthotopic mouse models the…

Philip McCarthy, MD of Roswell Park discusses New Strategy for Controlling Graft vs. Host Disease in Blood/Marrow Transplant Recipients. New preclinical work by a team of researchers from the Transplant and Cellular Therapy Program of the Roswell Park Comprehensive Cancer Center suggests that the risk of developing acute graft vs. host disease (GVHD) during allogeneic blood / marrow transplant (BMT), a potentially curative treatment for selected patients with hematologic disorders, can be minimized using an existing class of medications named Hemn Mohammadpour PhD, DVM, Philip McCarthy, MD, Elizabeth Repasky, PhD, and colleagues show in a new study in the journal…

Charles Edward Geyer, MD Houston Methodist discusses the ASCO 2020 abstract entitled Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer Bottom line: The KATHERINE Phase 3 analysis (NCT01772472) compared adjuvant T-DM1 versus H after neoadjuvant chemotherapy in patients with residual invasive breast cancer plus HER2-targeted therapy. Here we disclose exploratory analysis of the relationship between invasive disease-free survival (IDFS) and potentially reaction-related biomarkers. Approaches: Samples of fixed paraffin-embedded tissue were obtained before and/or in the course of neoadjuvant therapy.…

Jacob J. Adashek, DO of Moffit Cancer Center gives an overview from ASCO 2020 the abstract entitled Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities. Bottom line: Effects of immune control point blockade therapy (ICT) trials were primarily conducted in patients with melanoma and lung cancer, both of which are enriched for White patients. A National Cancer Database report, for example, showed that 97 per cent of melanoma first-line ICT therapies were given to White recipients (Patel, ASCO-SITC 2020). Because of the expanding indication of tumor types affecting more diverse populations, we tried to research whether…

Ravi Salgia, MD, PhD from City of Hope and the AACR 2020 meeting discusses the AACR 2020 abstract entitled Association of molecular characteristics with survival in advanced NSCLC patients treated with checkpoint inhibitors Summary Objectives: Immune checkpoint inhibitors (ICIs) modified the lung cancer therapy environment. Large proportions of patients however have primary or developed ICI resistance. Molecular characterization is crucial to the selection of patients and to overcoming resistance to inhibitors in checkpoints. This research aims to examine the molecular characteristics associated with ICI outcomes in advanced patients with non-small cell lung cancer ( NSCLC). Materials and methods: All City…

Cathy Eng, MD at Vanderbilt University Medical Center discusses Anal cancer’s first randomized trial for inoperable disease sets the treatment standard Patients with inoperable anal cancer, a rare condition, have not had a regular treatment so far; palliative care was the norm for them. Now the Journal of Clinical Oncology is releasing findings from InterAAct, the first international prospective randomized trial in advanced anal cancer. In 91 patients the study compared two different chemotherapy therapies. The primary outcome, Objective response rate (ORR), was the same between treatments. The ORR for cisplatin plus 5-fluorouracil (5FU) in carboplatin plus paclitaxel was 57…

Scott Tomlins, MD, Ph.D. Co-Founder, and Chief Scientific Officer – Strata discusses the Strata Oncology Partners with Elevation Oncology to Accelerate Enrollment of CRESTONE Study for Patients with Rare NRG1 Gene Fusions. Press Release – ANN ARBOR, Mich., July 21, 2020 / PRNewswire/ — Strata Oncology, Inc., a precision oncology company developing molecular targets for cancer therapies, today announced the signing of an agreement with the newly launched Elevation Oncology to facilitate patient detection and registration for the Phase 2 CRESTONE Elevation Oncology trial evaluating seribantumab use in recurrent patients; Seribantumab is a fully human monoclonal IgG2 antibody that binds…

Audrey Guth, Nanny Angel Network – Astellas Oncology discusses Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award the Best Innovations in Cancer Care Beyond Medicine.http://www.c3prize.comhttps://nannyangelnetwork.com/

Eric Jonasch, MD @MDAndersonNews #ASCO2020 gives an overview of the Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease Bottom line: Von Hippel-Lindau disease (VHL) patients (pts) are at risk for multiple cancers including strong renal cell carcinoma (ccRCC). VHL inactivation results in constitutive activation of the transcription factor HIF-2α, which induces development of the tumors. In a phase 1/2 analysis, MK-6482, a potent, selective, small molecule inhibitor of HIF-2α, showed favorable safety and antitumor activity. For the treatment of VHL-associated ccRCC (NCT03401788), we present initial findings of the open-label phase 2 analysis on MK-6482. Approaches:…

Abby Westerman, founder of b-present Foundation – Astellas discusses Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award the Best Innovations in Cancer Care Beyond Medicinehttps://b-present.orghttp://www.c3prize.com

Elizabeth Plimack, MD @FoxChaseCancer gives an updated analysis of KEYNOTE-426 at ASCO 2020 Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) Bottom line: The randomized, open-label, phase 3 research KEYNOTE-426 (NCT02853331) showed that pembrolizumab (pembro) + axitinib (axi) significantly improved OS, PFS, and ORR vs. sunitinib as first-line therapy for advanced RCC (aRCC) in the first pre-planned interim review (minimum follow-up research of 7 mo). Updated analysis as seen here. Approaches: Treatment-naive patients (pts) with clear cell aRCC, KPS approximately 70%, and detectable disease (RECIST v1.1) were randomly allocated to receive pembro 200 mg…

Jared Gollob Chief Medical Officer @KymeraTx shares common questions he gets from colleagues such as “What’s Advantage of IRAK 4 Combined into One Molecule?” and others on the AACR 2020 presentation entitled IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology Kymera Therapeutics , Inc., a biotechnology company pioneering targeted protein degradation to develop innovative protein degrading medicines for patients, today announced that it will present preclinical data on its potent and highly selective STAT3 degraders, as well as first data from its novel IRAKIMiD degraders combining IRAK4 and…

Jared Gollob @JaredGollob @KymeraTx gives an overview of a poster presented at AACR 2020 IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders Kymera Therapeutics , Inc., a biotechnology company pioneering targeted protein degradation to develop innovative protein degrading medicines for patients, today announced that it will present preclinical data on its potent and highly selective STAT3 degraders, as well as first data from its novel IRAKIMiD degraders combining IRAK4 and IMiD substrate degradation. Data will be discussed during the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II…

Astrid Margossian, MD @SEngineMedicine discusses an ASCO 2020 poster entitled Predictive value of a CLIA-approved organoid based drug sensitivity test Bottom line: Precision medicine incorporates genomic, biochemical, and clinical knowledge in order to improve the selection of cancer patients for treatment. Drug research with Ex vivo has the ability to fit the right drug to the right patient. For all solid tumors, we have established a CLIA-certified functional drug assay which provides an actionable report of organoid sensitivity to targeted, endocrine and chemotherapy agents as a tool for therapeutic decisions. Objectives: To develop the predictive power of the test in…

Andy Krivoshik, MD, Ph.D. – Astellas Oncology discusses Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award the Best Innovations in Cancer Care Beyond Medicine.http://www.c3prize.com

Robin Kate Kelley, MD of the University of California, San Francisco discusses the most effective way to combined a CTL4 inhibitor with a PDL1 inhibitor. Bottom line: In the initial cohort of this study (NCT02519348), the combination of double immune control point inhibitors (ICI) T (anti – CTLA-4) and D (anti – PD-L1) showed tolerability with positive objective response rate (ORR). Subsequent assessment of pts with solid tumors treated with can doses of T indicated priming with a higher dose of T can induce a stronger immune response and improve anti-tumor activity. The randomized expansion cohorts thus included 4 arms…

Robin Kate Kelley, MD gives an overview of a presentation from ASCO 2020 entitled Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). Bottom line: In the initial cohort of this study (NCT02519348), the combination of double immune control point inhibitors (ICI) T (anti – CTLA-4) and D (anti – PD-L1) showed tolerability with positive objective response rate (ORR). Subsequent assessment of pts with solid tumors treated with can doses of T indicated priming with a higher dose of T can induce a stronger…

Charles S. Fuchs, MD, MPH at Yale Cancer discusses how Checkpoint Inhibitors are a “real player” in Gastric Cancers. Bottom line: KEYNOTE-061 (NCT02370498) is a Phase 3 global analysis of pembrolizumab vs. paclitaxel as second line therapy for GC. At the time of primary analysis (data cutoff: Oct 26, 2017), pembrolizumab did not substantially extend overall survival ( OS) versus paclitaxel (9.1 months versus 8.3 months) in patients with PD-L1-positive status (combined positive score [CPS] [1]), but resulted in a longer response period (DOR) and a favorable safety profile versus paclitaxel. After 2 additional years of follow-up (cut-off: Oct 7,…

Charles S. Fuchs, MD, MPH at Yale Cancer discusses the Current Role for Pembrolizumab in Gastric Cancer using the latest data from the phase III KEYNOTE-061 trial. Bottom line: KEYNOTE-061 (NCT02370498) is a Phase 3 global analysis of pembrolizumab vs. paclitaxel as second line therapy for GC. At the time of primary analysis (data cutoff: Oct 26, 2017), pembrolizumab did not substantially extend overall survival ( OS) versus paclitaxel (9.1 months versus 8.3 months) in patients with PD-L1-positive status (combined positive score [CPS] [1]), but resulted in a longer response period (DOR) and a favorable safety profile versus paclitaxel. After…

Charles S. Fuchs, MD, MPH at Yale Cancer gives an overview of a study presented at ASCO 2020 entitled Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial. Bottom line: KEYNOTE-061 (NCT02370498) is a Phase 3 global analysis of pembrolizumab vs. paclitaxel as second line therapy for GC. At the time of primary analysis (data cutoff: Oct 26, 2017), pembrolizumab did not substantially extend overall survival ( OS) versus paclitaxel (9.1 months versus 8.3 months) in patients with PD-L1-positive status (combined positive score [CPS] [1]), but…

Benjamin Tycko, MD of Hackensack Meridian Health explains his study findings on DNA that Pinpoint Risks for Cancers. By sequencing entire genomes for DNA modifications and analyzing cancer tissues as well as healthy tissues, Hackensack Meridian Health researchers and doctors have detected what may be a key to cancer threats and other diseases: unique DNA locations where certain expression changes (methylation) are imbalanced, according to a new paper. On June 29, the scientists, from the Center for Discovery and Innovation (CDI), Hackensack University Medical Center and its John Theurer Cancer Center (JTCC), and the Georgetown Lombardi Comprehensive Cancer Center Consortium,…

Benjamin Tycko, MD of Hackensack Meridian Health explains Classical Cancer Epigenetic vs Epigenetic Mapping. By sequencing entire genomes for DNA modifications and analyzing cancer tissues as well as healthy tissues, Hackensack Meridian Health researchers and doctors have detected what may be a key to cancer threats and other diseases: unique DNA locations where certain expression changes (methylation) are imbalanced, according to a new paper. On June 29, the scientists, from the Center for Discovery and Innovation (CDI), Hackensack University Medical Center and its John Theurer Cancer Center (JTCC), and the Georgetown Lombardi Comprehensive Cancer Center Consortium, recognized by the National…

Benjamin Tycko, MD gives an overview of Signposts in DNA that Pinpoint Risks for Cancers and other Diseases. By sequencing entire genomes for DNA modifications and analyzing cancer tissues as well as healthy tissues, Hackensack Meridian Health researchers and doctors have detected what may be a key to cancer threats and other diseases: unique DNA locations where certain expression changes (methylation) are imbalanced, according to a new paper. On June 29, the scientists, from the Center for Discovery and Innovation (CDI), Hackensack University Medical Center and its John Theurer Cancer Center (JTCC), and the Georgetown Lombardi Comprehensive Cancer Center Consortium,…

First Lady Melania Trump chairs a White House roundtable discussing sickle cell anemia. 

Marian Navratil, P.h.D. of HTG Molecular Diagnostics discusses the power of RNA profiling now and in the future. This data was released at ASCO 2020 under the presentation Platform comparison of HTG EdgeSeq and RNA-Seq for gene expression profiling of tumor tissue specimens. Background: Clinical biomarker studies are often hindered by the availability of tissue specimens of sufficient quality and quantity. While RNA-Seq is often considered the gold standard for measuring mRNA expression levels in cancer tissue, it typically requires multiple formalin-fixed paraffin-embedded (FFPE) tissue sections to extract a sufficient amount of quality RNA for subsequent gene expression profiling analysis.…

Marian Navratil, P.h.D. of HTG Molecular Diagnostics discusses the future of RNA profiling and using it for detecting inflammation of tumor This data was released at ASCO 2020 under the presentation Platform comparison of HTG EdgeSeq and RNA-Seq for gene expression profiling of tumor tissue specimens. Background: Clinical biomarker studies are often hindered by the availability of tissue specimens of sufficient quality and quantity. While RNA-Seq is often considered the gold standard for measuring mRNA expression levels in cancer tissue, it typically requires multiple formalin-fixed paraffin-embedded (FFPE) tissue sections to extract a sufficient amount of quality RNA for subsequent gene…

Marian Navratil, P.h.D. of HTG Molecular Diagnostics How HGT is Different than RNAPlatform comparison of HTG EdgeSeq and RNA-Seq for gene expression profiling of tumor tissue specimens from ASCO 2020 Background: Clinical biomarker studies are often hindered by the availability of tissue specimens of sufficient quality and quantity. While RNA-Seq is often considered the gold standard for measuring mRNA expression levels in cancer tissue, it typically requires multiple formalin-fixed paraffin-embedded (FFPE) tissue sections to extract a sufficient amount of quality RNA for subsequent gene expression profiling analysis. The HTG EdgeSeq technology is a gene expression profiling platform that combines quantitative…

Marian Navratil, P.h.D. of HTG Molecular Diagnostics gives an overview from ASCO 2020 the Platform comparison of HTG EdgeSeq and RNA-Seq for gene expression profiling of tumor tissue specimens. Background: Clinical biomarker studies are often hindered by the availability of tissue specimens of sufficient quality and quantity. While RNA-Seq is often considered the gold standard for measuring mRNA expression levels in cancer tissue, it typically requires multiple formalin-fixed paraffin-embedded (FFPE) tissue sections to extract a sufficient amount of quality RNA for subsequent gene expression profiling analysis. The HTG EdgeSeq technology is a gene expression profiling platform that combines quantitative nuclease…

Melissa Johnson, MD, Associate Director, Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology discusses CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer. ASCOhttps://meetinglibrary.asco.org/record/185085/abstract

Kathryn Lang, MD – Guardant Health, is this available today. The data presented at the AACR 2020 show that the LUNAR-2 assay achieved 90% sensitivity and 94% specificity in detecting early-stage CRC.1 When restricting analysis of the controls to those who were negative for CRC by colonoscopy (n=74), the LUNAR-2 assay demonstrated improved specificity (99%) with no reduction in sensitivity. These results are consistent with previously reported data2 showing that the company’s multi-modal, cancer-specific circulating tumor DNA (ctDNA) technology increases test sensitivity to deliver clinically meaningful results.

Kathryn Lang, MD of Guardant Health discusses Restricting Cohort to Negative Test Results with Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal Cancer. This data was presented at AACR 2020 that shows that the LUNAR-2 assay achieved 90% sensitivity and 94% specificity in detecting early-stage CRC.1 When restricting analysis of the controls to those who were negative for CRC by colonoscopy (n=74), the LUNAR-2 assay demonstrated improved specificity (99%) with no reduction in sensitivity. These results are consistent with previously reported data2 showing that the company’s multi-modal, cancer-specific circulating tumor DNA (ctDNA) technology increases test sensitivity to deliver clinically meaningful…

Kathryn Lang, MD of Guardant Health provides an overview of data presented at AACR 2020 that shows that the LUNAR-2 assay achieved 90% sensitivity and 94% specificity in detecting early-stage CRC.1 When restricting analysis of the controls to those who were negative for CRC by colonoscopy (n=74), the LUNAR-2 assay demonstrated improved specificity (99%) with no reduction in sensitivity. These results are consistent with previously reported data2 showing that the company’s multi-modal, cancer-specific circulating tumor DNA (ctDNA) technology increases test sensitivity to deliver clinically meaningful results.

Melissa Johnson, MD, Associate Director, Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology discusses CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer. ASCOhttps://meetinglibrary.asco.org/record/185085/abstract

Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor